SJ Isakoff

483 total citations
29 papers, 347 citations indexed

About

SJ Isakoff is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, SJ Isakoff has authored 29 papers receiving a total of 347 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in SJ Isakoff's work include Advanced Breast Cancer Therapies (10 papers), Cancer Treatment and Pharmacology (10 papers) and PARP inhibition in cancer therapy (7 papers). SJ Isakoff is often cited by papers focused on Advanced Breast Cancer Therapies (10 papers), Cancer Treatment and Pharmacology (10 papers) and PARP inhibition in cancer therapy (7 papers). SJ Isakoff collaborates with scholars based in United States, Australia and France. SJ Isakoff's co-authors include Eric P. Winer, R. S. Gelman, Nadine Tung, Paul E. Goss, Leif W. Ellisen, Vincent L. Giranda, Beth Overmoyer, Karleen Habin, J. E. Garber and Barbara L. Smith and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

SJ Isakoff

27 papers receiving 333 citations

Peers

Countries citing papers authored by SJ Isakoff

Since Specialization

Citations

This map shows the geographic impact of SJ Isakoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by SJ Isakoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites SJ Isakoff more than expected).

Fields of papers citing papers by SJ Isakoff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by SJ Isakoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by SJ Isakoff. The network helps show where SJ Isakoff may publish in the future.

Co-authorship network of co-authors of SJ Isakoff

This figure shows the co-authorship network connecting the top 25 collaborators of SJ Isakoff. A scholar is included among the top collaborators of SJ Isakoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with SJ Isakoff. SJ Isakoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract GS2-03: Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality, stratified by breast cancer subtypes and adjuvant chemotherapy usage: Individual patient-level meta-analyses of over 27,000 patients 2019 ·Cancer Research ·(unknown), Geoffrey Fell, Andrea Arfè, Lorenzo Trippa, Rachel A. Greenup, Kerry L. Reynolds, B. L. Smith, Beverly Moy, SJ Isakoff, Giovanni Parmigiani, Aditya Bardia	33
2	Abstract P2-11-01: Safety and efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) as ≥3rd-line therapeutic option for treatment-refractory HER2-negative metastatic breast cancer (HER2Neg mBC) 2019 ·Cancer Research ·Kevin Kalinsky, SJ Isakoff, SM Tolaney, Dejan Juric, IA Mayer, Linda T. Vahdat, Jennifer R. Diamond, Joyce O’Shaughnessy, R Moroose, (unknown), (unknown), (unknown), D M Goldenberg, (unknown), (unknown), (unknown), Raffaele Iannone, Aditya Bardia	3
3	Abstract GS1-07: Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results 2018 ·Cancer Research ·Aditya Bardia, Linda T. Vahdat, Jennifer R. Diamond, Kevin Kalinsky, Joyce O’Shaughnessy, R Moroose, SJ Isakoff, SM Tolaney, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), D M Goldenberg, IA Mayer	12
4	Abstract P1-12-03: Association between tumor genotype and development of brain metastases in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer 2017 ·Cancer Research ·(unknown), L E Henderson, SJ Isakoff, Beverly Moy, (unknown), (unknown), Dora Dias‐Santagata, (unknown), A. John Iafrate, (unknown), Aditya Bardia, Dejan Juric	1
5	Abstract P3-07-12: Homologous recombination deficiency (HRD) as a predictive biomarker of response to neoadjuvant platinum-based therapy in patients with triple negative breast cancer (TNBC): A pooled analysis 2016 ·Cancer Research ·(unknown), A McMillan, (unknown), (unknown), (unknown), SJ Isakoff, VG Kaklamani, William J. Gradishar, Vered Stearns, (unknown), Sibylle Loibl, (unknown), Kirsten M. Timms, A-R Hartman, Gϋnter von Minckwitz	11
6	Abstract P5-13-02: Neoadjuvant endocrine therapy for estrogen receptor (ER) positive breast cancer: Comprehensive systematic review and meta-analysis 2016 ·Cancer Research ·Laura M. Spring, Arjun Gupta, (unknown), (unknown), SJ Isakoff, (unknown), Beverly Moy, Aditya Bardia	2
7	Phase Ib Dose-Escalation Study of the Akt Inhibitor Ipatasertib (Ipat) with Paclitaxel (P) in Patients (Pts) with Advanced Solid Tumors 2014 ·Annals of Oncology ·SJ Isakoff, Jeffrey R. Infante, Dejan Juric, Wai‐Yee Chan, (unknown), Luna Musib, Jian Zhu, (unknown), (unknown), Johanna C. Bendell	6
8	Abstract OT1-4-02: Phase I study of the combination of BKM120 and olaparib for the treatment of high grade serous ovarian cancer (HGSC) and triple negative breast cancer (TNBC) 2013 ·Cancer Research ·U. Matulonis, (unknown), Lewis C. Cantley, (unknown), (unknown), (unknown), C. Whalen, SJ Isakoff, Shannon N. Westin, K.M. Bell-McGuinn, EP Winer	0
9	Abstract P2-16-01: A randomized, phase II, multicenter, double-blind, placebo-controlled trial evaluating onartuzumab with or without bevacizumab in combination with weekly paclitaxel in locally recurrent or metastatic triple-negative breast cancer (TNBC) 2013 ·Cancer Research ·Véronique Dièras, Denise A. Yardley, Gilles Romieu, Vicente Valero, SJ Isakoff, Hartmut Koeppen, Holger Thurm, (unknown), Mario Campone, Simonetta Mocci	7
10	Abstract OT1-4-01: Multicenter phase II trial of the novel compound PM01183 (P) in BRCA1/2-associated or unselected metastatic breast cancer (MBC) 2013 ·Cancer Research ·SJ Isakoff, Cristina Cruz, J. E. Garber, Aňa Lluch, (unknown), Nadine Tung, Concepción Fernández, Carmen Kahatt, Sergio Szyldergemajn, (unknown), J. Baselga, Judith Balmañà	1
11	Abstract OT2-3-07: A randomized, phase 2 study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with temozolomide (TMZ) or in combination with carboplatin (C) and paclitaxel (P) versus placebo plus C/P in subjects with BRCA1 or BRACA2 mutation and metastatic breast cancer 2012 ·Cancer Research ·SJ Isakoff, (unknown), (unknown), Nancy Falotico, Bella Kaufman, Michael Friedländer, Mark E. Robson, Susan M. Domchek, (unknown), Evelyn McKeegan, Brenda Chyla, Jane Qian, (unknown)	4
12	Abstract P6-10-05: SU2C Phase 1b Trial of Dual PI3K/ mTOR Inhibitor BEZ235 with Letrozole in ER+/HER2− Metastatic Breast Cancer (MBC) 2012 ·Cancer Research ·IA Mayer, (unknown), Justin M. Balko, SJ Isakoff, Andres Forero, (unknown), (unknown), Y Li, Eric P. Winer, (unknown)	1
13	Abstract P6-05-02: Endocrine biomarkers in response to AR-inhibition with bicalutamide for the treatment of AR(+), ER/PR(−) metastatic breast cancer (MBC) (TBCRC011) 2012 ·Cancer Research ·Ayca Gucalp, Sara M. Tolaney, SJ Isakoff, James N. Ingle, MC Liu, LA Carey, (unknown), Hope S. Rugo, Lisle M. Nabell, Andres Forero, Vered Stearns, Lamia F. Momen, (unknown), Arooj Akhtar, (unknown), Sujata Patil, (unknown), (unknown), (unknown)	1
14	Abstract PD09-03: Impact of BRCA1/2 Mutation Status in TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple negative breast cancer. 2012 ·Cancer Research ·SJ Isakoff, (unknown), (unknown), Tiffany A. Traina, LA Carey, (unknown), MC Liu, Hope S. Rugo, Vered Stearns, Steven E. Come, Dianne M. Finkelstein, A-R Hartman, J. E. Garber, (unknown), EP Winer, (unknown)	5
15	TBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR+/ER-/PR- metastatic breast cancer (MBC). 2011 ·Journal of Clinical Oncology ·Ayca Gucalp, SM Tolaney, SJ Isakoff, J. N. Ingle, (unknown), LA Carey, K. L. Blackwell, H. S. Rugo, Lisle Nabell, A. Abbruzzi, José González, D. D. Giri, (unknown), (unknown), Gabriella D’Andrea, (unknown), Pamela Drullinsky, Nancy T. Sklarin, C. Hudis, (unknown)	4
16	TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. 2011 ·Journal of Clinical Oncology ·SJ Isakoff, Paul E. Goss, Erica L. Mayer, Tiffany A. Traina, LA Carey, Karen J. Krag, H. S. Rugo, (unknown), Vered Stearns, SE Come, Darrell R. Borger, (unknown), Dianne M. Finkelstein, J. E. Garber, (unknown), Eric P. Winer, Leif W. Ellisen	30
17	OT2-05-02: ACRIN 6691 Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging (DOSI). 2011 ·Cancer Research ·(unknown), (unknown), (unknown), (unknown), (unknown), Rita S. Mehta, (unknown), (unknown), NM Hylton, P. Kaufman, (unknown), (unknown), (unknown), David A. Boas, SJ Isakoff	4
18	ACRIN 6691 monitoring and predicting breast cancer neoadjuvant chemotherapy response using diffuse optical spectroscopic imaging (DOSI). 2011 ·Journal of Clinical Oncology ·(unknown), Janet Butler, David A. Mankoff, SJ Isakoff, (unknown), Arjun G. Yodh, David A. Boas, (unknown), Brian W. Pogue, (unknown), Rita S. Mehta, Philip M. Carpenter, (unknown), (unknown), (unknown), (unknown)	2
19	A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. 2010 ·Journal of Clinical Oncology ·SJ Isakoff, Beth Overmoyer, Nadine Tung, R. S. Gelman, Vincent L. Giranda, (unknown), Karleen Habin, Leif W. Ellisen, Eric P. Winer, Paul E. Goss	122
20	A phase I study of vandetanib and metronomic chemotherapy in advanced breast cancer. 2009 ·Cancer Research ·(unknown), SJ Isakoff, (unknown), Jennifer Savoie, Joan D. Beckman, Giannoula Klement, R. S. Gelman, EP Winer, HJ Burstein	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact